IP Verse

Methods For Treating Hcv - EP2709613

The patent EP2709613 was granted to Gilead Pharmasset on Aug 12, 2020. The application was originally filed on Sep 14, 2012 under application number EP12768967A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2709613

GILEAD PHARMASSET
Application Number
EP12768967A
Filing Date
Sep 14, 2012
Status
Patent Maintained As Amended
Jul 10, 2020
Grant Date
Aug 12, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GILLARDAug 22, 2018ELKINGTON AND FIFEADMISSIBLE

Patent Citations (21) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20090632194-
DESCRIPTIONEP0093401
DESCRIPTIONUS2009257978
DESCRIPTIONUS2010051763
DESCRIPTIONUS2010081628
DESCRIPTIONUS2010298257
DESCRIPTIONUS2010310512
DESCRIPTIONUS2011015146
DESCRIPTIONUS7429572
DESCRIPTIONUS7754720
DESCRIPTIONUS7964580
DESCRIPTIONWO2007056170
INTERNATIONAL-SEARCH-REPORTUS2011178129
INTERNATIONAL-SEARCH-REPORTUS2011306541
INTERNATIONAL-SEARCH-REPORTWO2012087596
OPPOSITIONEP2583677
OPPOSITIONEP2583680
OPPOSITIONUS2011178129
OPPOSITIONUS2011306541
OPPOSITIONWO2010132601
OPPOSITIONWO2012087596

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- ERIC J LAWITZ ET AL, "A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C", JOURNAL OF HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 57, no. 1, doi:10.1016/J.JHEP.2011.12.029, ISSN 0168-8278, (20111229), pages 24 - 31, (20120205), XP028493090
EXAMINATION- LAM ANGELA M ET AL, "PSI-7851, a pronucleotide of .beta.-D-2'-deoxy-2'-fluoro-2'-C- methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 54, no. 8, doi:10.1128/AAC.00399-10, ISSN 0066-4804, (20100801), pages 3187 - 3196, (20100601), XP009151247
OPPOSITION- DELANG et al., Viruses, (20100000), vol. 2, no. 4, pages 826 - 866-
OPPOSITION- "Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN inTreatment-Naïve Patients With HCV GT2 or GT3", www.clinicaltrial.gov, (20141107), URL: https://clinicaltrials.gov/ct2/show/NCT01260350, XP055515743-
OPPOSITION- peter York, "chapter 1, chapter 20", peter York, M.E. AULTON, Pharmaceutics: The Science of Dosage Form Design, London, (20010000), pages 1 - 6,289-295, XP055515789-
OPPOSITION- P. FERENCI et al., "Treatment of chronic hepatitis C - are interferons really necessary?", Liver International, (20120201), vol. 32, pages 108 - 112-
OPPOSITION- Sofia et al, Antiviral Chemistry and Chemotherapy, (20110000), vol. 22, pages 23 - 49-
OPPOSITION- Soriano et al, Journal of Antimicrobial. Chemotherapy, (20110000), vol. 66, pages 1673 - 1686-
OPPOSITION- sss.clinicaltrial.gov NCT01260350-
OPPOSITION- P. HALFON et al., "Hepatitis C virus resistance to protease inhibitors", Journal of Hepatology, (20110120), vol. 55, no. 1, pages 192 - 206, XP028242506
OPPOSITION- E.J. LAWITZ et al., "A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C", Journal of Hepatology, (20111229), vol. 57, no. 1, pages 24 - 31, XP028493090
OPPOSITION- E. MURAKAMI et al., "Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977", Journal of Biological Chemistry, (20100000), vol. 285, no. 45, pages 34337 - 34347, XP055004551
OPPOSITION- P. FERENCI et al., "Treatment of chronic hepatitis C - are interferons really necessary?", Liver International, (20120201), vol. 32, pages 108 - 112, XP055048144
OPPOSITION- A.M. LAM et al., "PSI-7851, a pronucleotide of .beta.-D-2'-deoxy-2'-fluoro-2'-C- methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication", Antimicrobial Agents and Chemotherapy , American Society for Microbiology, (20100801), vol. 54, no. 8, pages 3187 - 3196, XP009151247
OPPOSITION- DELANG et al., "anitiviral therapy for hepatitis c virus :beyond the standard of care", Viruses, (20100000), vol. 2, no. 4, pages 826 - 866, XP055515758

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents